Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 6/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 2/20 | 0.32 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.32 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8547909 | 0.89 | KDR (0.37) | NOS1ALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL8542648 | 0.84 | ALDH1A1 (0.37) | SLC6A9NOS1ALDH1A1ADORA3CTSA | |
| SCHEMBL8935948 | 0.82 | ADORA2A (0.36) | SLC6A9NOS1ALDH1A1LMNAHTT | |
| SCHEMBL7717266 | 0.82 | ADORA2A (0.37) | SLC6A9NOS1ALDH1A1LMNAHTT | |
| SCHEMBL30803820 | 0.82 | ADORA2A (0.37) | SLC6A9NOS1ALDH1A1LMNAHTT | |
| SCHEMBL4244108 | 0.81 | ALDH1A1 (0.34) | NOS1ALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL8936038 | 0.81 | ADORA2A (0.37) | SLC6A9NOS1ALDH1A1LMNAHTT | |
| SCHEMBL905936 | 0.80 | ALDH1A1 (0.34) | NOS1ALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL7770333 | 0.76 | ADORA2A (0.44) | SLC6A9ALDH1A1ADORA3 | |
| SCHEMBL8597197 | 0.75 | ADORA3 (0.32) | ALDH1A1LMNAHTTL3MBTL1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040022735-A1 | Enzyme activated contrast agents | GENERAL ELECTRIC COMPANY | 2004-02-05 | — | — | US | claimed |
| US-20020076378-A1 | Polymers | NYCOMED IMAGING AS | 2002-06-20 | — | — | US | claimed |
| US-20160152687-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9296809-B2 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9221896-B2 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150329619-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150203568-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-8993517-B2 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8969538-B2 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140328794-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140303077-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20030180296-A1 | Antibodies that immunospecifically bind to trail receptors | HUMAN GENOME SCIENCES, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6610269-B1 | Disease state imaged using a targeted contrast agent of the formula V-L-R, where V is a vector moiety having affinity for an angiogenesis-related endothelial cell receptor, L is a linker, R is a macromolecular or particulate label | AMERSHAM HEALTH AS (NO) | 2003-08-26 | — | — | US | disclosed |
| US-6264914-B1 | CONTAINING IMIDAZOLE RING | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6051207-A | PHOSPHATIDYLSERINE LINKED ISOXAZOLE SULFONAMIDE DERIVATIVES; DIAGNOSING AND IMAGING CARDIOVASCULAR DISORDERS | NYCOMED IMAGING AS (NO) | 2000-04-18 | — | — | US | disclosed |
| EP-0624097-B1 | TARGETING RADIOACTIVE IMMUNOREAGENTS | NYCOMED IMAGING AS (NO) | 1998-03-18 | — | — | EP | disclosed |
| US-5707603-A | Pyridine complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions | NYCOMED IMAGING AS (NO) | 1998-01-13 | — | — | US | disclosed |
| US-5677445-A | DIAGNOSIS, THERAPY | NYCOMED IMAGING AS (NO) | 1997-10-14 | — | — | US | disclosed |
| EP-0624097-A1 | TARGETING RADIOACTIVE IMMUNOREAGENTS | NYCOMED IMAGING AS (NO) | 1994-11-17 | — | — | EP | disclosed |
| WO-1992008494-A2 | TARGETING RADIOACTIVE IMMUNOREAGENTS | STERLING WINTHROP INC. (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329619-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, HDGF | SLC6A9 2650/4885NOS1 4280/4885ALDH1A1 2350/4885 |
| US-20150203568-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, HDGF | SLC6A9 2650/4885NOS1 4280/4885ALDH1A1 2350/4885 |
| US-20160152687-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, HDGF | SLC6A9 2650/4885NOS1 4280/4885ALDH1A1 2350/4885 |
| US-20140303077-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, HDGF | SLC6A9 2650/4885NOS1 4280/4885ALDH1A1 2350/4885 |
| US-20020076378-A1 | Polymers | PARG, PAICS, PIGO | SLC6A9 2354/4885NOS1 1691/4885ALDH1A1 2505/4885 |
| US-20140328794-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, IAPP | SLC6A9 2653/4885NOS1 4069/4885ALDH1A1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.